The NHS introduced an early access treatment programme for Hepatitis C for those with the greatest clinical need. This gave patients with decompensated cirrhosis access to sofosbuvir ahead of it being available in August 2015, as well as other new DAAs. Read more about The NHS introduced an early access treatment programme for Hepatitis C for those with the greatest clinical need. This gave patients with decompensated cirrhosis access to sofosbuvir ahead of it being available in August 2015, as well as other new DAAs.
David Cameron did not indicate any interest in pursuing the option of accelerated Hepatitis C treatment. Read more about David Cameron did not indicate any interest in pursuing the option of accelerated Hepatitis C treatment.
Jeremy Hunt, as the Secretary of State for Health, wrote to David Cameron, setting out three options for support to replace the existing Alliance House Organisations. One option he proposed was that the 2,500 people within "the infected blood cohort" who had not thus far had accelerated access to sofosbuvir-linked treatments should be funded to receive it. Read more about Jeremy Hunt, as the Secretary of State for Health, wrote to David Cameron, setting out three options for support to replace the existing Alliance House Organisations. One option he proposed was that the 2,500 people within "the infected blood cohort" who had not thus far had accelerated access to sofosbuvir-linked treatments should be funded to receive it.
The day the Penrose Report was published, Prime Minister, David Cameron, announced "up to 25 million in 2015-16 to support any transitional arrangements to a better payments system." Read more about The day the Penrose Report was published, Prime Minister, David Cameron, announced "up to 25 million in 2015-16 to support any transitional arrangements to a better payments system."
The Guardian published an article reporting that the Hepatitis C drug, sofosbuvir, had been delayed by the NHS due to its high cost. Read more about The Guardian published an article reporting that the Hepatitis C drug, sofosbuvir, had been delayed by the NHS due to its high cost.
NICE issued guidelines for treatment of Hepatitis C with sofosbuvir. This would normally lead to compliance within 3 months. However, NHS England requested that implementation be delayed until 31 July 2015. Four reasons were put forward for the delay. Read more about NICE issued guidelines for treatment of Hepatitis C with sofosbuvir. This would normally lead to compliance within 3 months. However, NHS England requested that implementation be delayed until 31 July 2015. Four reasons were put forward for the delay.
Strategic Framework and Action Plan for the Prevention and Control of Hepatitis C in Northern Ireland was published. Read more about Strategic Framework and Action Plan for the Prevention and Control of Hepatitis C in Northern Ireland was published.
Scotland was cited by WHO as a "model country" in terms of its response to the Hepatitis C challenge. Read more about Scotland was cited by WHO as a "model country" in terms of its response to the Hepatitis C challenge.
The second phase of the Hepatitis C Action Plan was introduced in Scotland, which published the results of data gathering, showing that an insufficient number of people were being diagnosed and receiving antiviral treatment and that there were inequalities across Scotland in treatment. Read more about The second phase of the Hepatitis C Action Plan was introduced in Scotland, which published the results of data gathering, showing that an insufficient number of people were being diagnosed and receiving antiviral treatment and that there were inequalities across Scotland in treatment.
The Hepatitis C Action Plan set out a framework for how to implement a treatment strategy. It identified that treatment services varied across different parts of the country and detailed a need for high-quality health services for the assessment and treatment of those with Hepatitis C Read more about The Hepatitis C Action Plan set out a framework for how to implement a treatment strategy. It identified that treatment services varied across different parts of the country and detailed a need for high-quality health services for the assessment and treatment of those with Hepatitis C